The path toward using microbial metabolites as therapies

EBioMedicine

Volumn 44, Issue , 2019, Pages 747-754

  Descamps, Hélène C ^a   Herrmann, Beatrice ^a   Wiredu, Daphne ^a   Thaiss, Christoph A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disease; Metabolites; Microbiome; Post biotics; Therapies

Indexed keywords

ARACHIDONIC ACID; AROMATIC HYDROCARBON RECEPTOR; BETAINE; BILE ACID; BUTYRIC ACID; CARNITINE; CHOLINE; CRESOL; FARNESOID X RECEPTOR; FLAVONOID; G PROTEIN COUPLED RECEPTOR; GUGGULSTERONE; HISTONE DEACETYLASE; INDOLE; INDOLEACETIC ACID; LINOLEIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLCHOLINE; POLYAMINE; RETINOIC ACID; SHORT CHAIN FATTY ACID; TAURINE; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE; TYROSINE; UNINDEXED DRUG; UREMIC TOXIN; FATTY ACID; METHYLAMINE; TRIMETHYLOXAMINE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTISM; BACTEROIDES THETAIOTAOMICRON; CANCER INHIBITION; CANDIDA ALBICANS; CEREBROSPINAL FLUID; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY FAILURE; CITROBACTER RODENTIUM; CLOSTRIDIUM SPOROGENES; ENTEROCOCCUS FAECALIS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INSULIN SENSITIVITY; INTRAEPITHELIAL LYMPHOCYTE; LACTOBACILLUS PLANTARUM; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; METABOLITE; METABOLOMICS; MICROBIOME; NERVOUS SYSTEM DEVELOPMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIORITY JOURNAL; REVIEW; SARCOPENIA; SCHIZOPHRENIA; STEROL METABOLISM; THROMBOSIS; ANIMAL; DISEASE PREDISPOSITION; ENERGY METABOLISM; INTESTINE FLORA; METABOLISM;

ANIMALS; DISEASE SUSCEPTIBILITY; ENERGY METABOLISM; FATTY ACIDS; GASTROINTESTINAL MICROBIOME; HUMANS; METHYLAMINES;

EID: 85067025173     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2019.05.063     Document Type: Review

References (127)

1. Levy, M., Kolodziejczyk, A.A., Thaiss, C.A., Elinav, E., Dysbiosis and the immune system. Nat Rev Immunol 17:4 (Apr 2017), 219–232.
2. Thaiss, C.A., Elinav, E., The remedy within: will the microbiome fulfill its therapeutic promise?. J Mol Med (Berl) 95:10 (2017), 1021–1027.
3. Bennett, B.J., de Aguiar Vallim, T.Q., Wang, Z., et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17:1 (2013), 49–60.
4. Tan, Y., Sheng, Z., Zhou, P., et al. Plasma Trimethylamine N-oxide as a novel biomarker for plaque rupture in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv, 12(1), 2019, e007281.
5. Zhuang, R., Ge, X., Han, L., et al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis. Obes Rev 20:6 (Jun 2019), 883–894.
6. Haghikia, A., Li, X.S., Liman, T.G., et al. Gut microbiota-dependent Trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to Proinflammatory monocytes. Arterioscler Thromb Vasc Biol 38:9 (2018), 2225–2235.
7. Li, X.S., Wang, Z., Cajka, T., et al. Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. JCI Insight, 3(6), 2018.
8. Missailidis, C., Hallqvist, J., Qureshi, A.R., et al. Serum Trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS One, 11(1), 2016, e0141738.
9. Stubbs, J.R., Stedman, M.R., Liu, S., et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with end-stage kidney disease receiving maintenance Hemodialysis. Clin J Am Soc Nephrol, Jan 21 2019, 10.2215/CJN.06190518 (pii: CJN.06190518).
10. Vogt, N.M., Romano, K.A., Darst, B.F., et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimers Res Ther, 10(1), 2018, 124.
11. Wang, Z., Klipfell, E., Bennett, B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:7341 (2011), 57–63.
12. Koeth, R.A., Wang, Z., Levison, B.S., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:5 (2013), 576–585.
13. Zhu, W., Buffa, J.A., Wang, Z., et al. Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk. J Thromb Haemost 16:9 (2018), 1857–1872.
14. Warrier, M., Shih, D.M., Burrows, A.C., et al. The TMAO-generating enzyme Flavin Monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep 10:3 (Jan 20 2015), 326–338.
15. Ding, L., Chang, M., Guo, Y., et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids Health Dis, 17(1), 2018, 286.
16. Gautam, A., Paudel, Y.N., Abidin, S., Bhandari, U., Guggulsterone, a farnesoid X receptor antagonist lowers plasma trimethylamine- N-oxide levels: an evidence from in vitro and in vivo studies. Hum Exp Toxicol, 960327118817862, 2018.
17. Zhu, W., Gregory, J.C., Org, E., et al. Gut microbial metabolite TMAO enhances platelet Hyperreactivity and thrombosis risk. Cell 165:1 (2016), 111–124.
18. Wang, Z., Roberts, A.B., Buffa, J.A., et al. Non-lethal inhibition of gut microbial Trimethylamine production for the treatment of atherosclerosis. Cell 163:7 (2015), 1585–1595.
19. Roberts, A.B., Gu, X., Buffa, J.A., et al. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 24:9 (2018), 1407–1417.
20. Velasquez, M.T., Ramezani, A., Manal, A., Raj, D.S., Trimethylamine N-oxide: the good, the bad and the unknown. Toxins (Basel), 8(11), 2016.
21. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Backhed, F., From dietary Fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165:6 (2016), 1332–1345.
22. Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111:6 (2014), 2247–2252.
23. Schulthess, J., Pandey, S., Capitani, M., et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 50:2 (2019), 432–45 e7.
24. Sun, M., Wu, W., Chen, L., et al. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat Commun, 9(1), 2018, 3555.
25. Smith, P.M., Howitt, M.R., Panikov, N., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:6145 (2013), 569–573.
26. Arpaia, N., Campbell, C., Fan, X., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:7480 (2013), 451–455.
27. Wu, W., Sun, M., Chen, F., et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol 10:4 (2017), 946–956.
28. Kim, M., Friesen, L., Park, J., Kim, H.M., Kim, C.H., Microbial metabolites, short-chain fatty acids, restrain tissue bacterial load, chronic inflammation, and associated cancer in the colon of mice. Eur J Immunol 48:7 (2018), 1235–1247.
29. Kimura, I., Ozawa, K., Inoue, D., et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun, 4, 2013, 1829.
30. Yoo, D.Y., Kim, W., Nam, S.M., et al. Synergistic effects of sodium butyrate, a histone deacetylase inhibitor, on increase of neurogenesis induced by pyridoxine and increase of neural proliferation in the mouse dentate gyrus. Neurochem Res 36:10 (2011), 1850–1857.
31. Slingerland, A.E., Schwabkey, Z., Wiesnoski, D.H., Jenq, R.R., Clinical evidence for the microbiome in inflammatory diseases. Front Immunol, 8, 2017, 400.
32. Puddu, A., Sanguineti, R., Montecucco, F., Viviani, G.L., Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm, 2014, 2014, 162021.
33. Hamer, H.M., Jonkers, D.M., Bast, A., et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28:1 (2009), 88–93.
34. van der Beek, C.M., Canfora, E.E., Lenaerts, K., et al. Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. Clin Sci (Lond) 130:22 (2016), 2073–2082.
35. Canfora, E.E., Jocken, J.W., Blaak, E.E., Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 11:10 (2015), 577–591.
36. Canfora, E.E., van der Beek, C.M., Jocken, J.W.E., et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Sci Rep, 7(1), 2017, 2360.
37. Cuomo, A., Maina, G., Rosso, G., et al. The microbiome: a new target for research and treatment of schizophrenia and its resistant presentations? A systematic literature search and review. Front Pharmacol, 9, 2018, 1040.
38. Erny, D., Hrabe de Angelis, A.L., Jaitin, D., et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18:7 (2015), 965–977.
39. Buffington, S.A., Di Prisco, G.V., Auchtung, T.A., Ajami, N.J., Petrosino, J.F., Costa-Mattioli, M., Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell 165:7 (2016), 1762–1775.
40. Bourassa, M.W., Alim, I., Bultman, S.J., Ratan, R.R., Butyrate, neuroepigenetics and the gut microbiome: can a high fiber diet improve brain health?. Neurosci Lett 625 (2016), 56–63.
41. Govindarajan, N., Agis-Balboa, R.C., Walter, J., Sananbenesi, F., Fischer, A., Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 26:1 (2011), 187–197.
42. Lopes-Borges, J., Valvassori, S.S., Varela, R.B., et al. Histone deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic metabolic alterations induced by ouabain. Pharmacol Biochem Behav 128 (2015), 89–95.
43. Burokas, A., Arboleya, S., Moloney, R.D., et al. Targeting the microbiota-gut-brain Axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol Psychiatry 82:7 (2017), 472–487.
44. Shibata, N., Kunisawa, J., Kiyono, H., Dietary and microbial metabolites in the regulation of host immunity. Front Microbiol, 8, 2017, 2171.
45. Hirata, S.I., Kunisawa, J., Gut microbiome, metabolome, and allergic diseases. Allergol Int 66:4 (2017), 523–528.
46. Kishino, S., Takeuchi, M., Park, S.B., et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc Natl Acad Sci U S A 110:44 (2013), 17808–17813.
47. Bassaganya-Riera, J., Hontecillas, R., Horne, W.T., et al. Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr 31:5 (2012), 721–727.
48. Kaikiri, H., Miyamoto, J., Kawakami, T., et al. Supplemental feeding of a gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, alleviates spontaneous atopic dermatitis and modulates intestinal microbiota in NC/nga mice. Int J Food Sci Nutr 68:8 (2017), 941–951.
49. Miyamoto, J., Mizukure, T., Park, S.B., et al. A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem 290:5 (2015), 2902–2918.
50. Gaullier, J.M., Halse, J., Hoivik, H.O., et al. Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese. Br J Nutr 97:3 (2007), 550–560.
51. Smedman, A., Vessby, B., Conjugated linoleic acid supplementation in humans—metabolic effects. Lipids 36:8 (2001), 773–781.
52. Sluijs, I., Plantinga, Y., de Roos, B., Mennen, L.I., Bots, M.L., Dietary supplementation with cis-9,trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults. Am J Clin Nutr 91:1 (2010), 175–183.
53. Seidner, D.L., Lashner, B.A., Brzezinski, A., et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 3:4 (2005), 358–369.
54. Hsiao, E.Y., McBride, S.W., Hsien, S., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155:7 (2013), 1451–1463.
55. Sridharan, G.V., Choi, K., Klemashevich, C., et al. Prediction and quantification of bioactive microbiota metabolites in the mouse gut. Nat Commun, 5, 2014, 5492.
56. Devlin, A.S., Marcobal, A., Dodd, D., et al. Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe 20:6 (2016), 709–715.
57. Rothhammer, V., Quintana, F.J., The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol 19:3 (2019), 184–197.
58. Metidji, A., Omenetti, S., Crotta, S., et al. The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity. Immunity 49:2 (2018), 353–62 e5.
59. Cervantes-Barragan, L., Chai, J.N., Tianero, M.D., et al. Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8alphaalpha(+) T cells. Science 357:6353 (2017), 806–810.
60. Zelante, T., Iannitti, R.G., Cunha, C., et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:2 (2013), 372–385.
61. Lamas, B., Richard, M.L., Leducq, V., et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 22:6 (2016), 598–605.
62. Beaumont, M., Neyrinck, A.M., Olivares, M., et al. The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB J 32 (2018), 6681–6693 (fj201800544).
63. Rothhammer, V., Mascanfroni, I.D., Bunse, L., et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22:6 (2016), 586–597.
64. Rothhammer, V., Borucki, D.M., Tjon, E.C., et al. Microglial control of astrocytes in response to microbial metabolites. Nature 557:7707 (2018), 724–728.
65. Apetoh, L., Quintana, F.J., Pot, C., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11:9 (2010), 854–861.
66. Duranton, F., Cohen, G., De Smet, R., et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23:7 (2012), 1258–1270.
67. Nakano, T., Katsuki, S., Chen, M., et al. Uremic toxin Indoxyl Sulfate promotes Proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-notch Signaling. Circulation 139:1 (2019), 78–96.
68. Triplett, T.A., Garrison, K.C., Marshall, N., et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol 36:8 (2018), 758–764.
69. Hamer, H.M., De Preter, V., Windey, K., Verbeke, K., Functional analysis of colonic bacterial metabolism: relevant to health?. Am J Physiol Gastrointest Liver Physiol 302:1 (2012), G1–G9.
70. Meijers, B.K., Van Kerckhoven, S., Verbeke, K., et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54:5 (2009), 891–901.
71. Opdebeeck, B., Maudsley, S., Azmi, A., et al. Indoxyl Sulfate and p-Cresyl Sulfate promote vascular calcification and associate with glucose intolerance. J Am Soc Nephrol 30:5 (2019), 751–766.
72. Bammens, B., Evenepoel, P., Keuleers, H., Verbeke, K., Vanrenterghem, Y., Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69:6 (2006), 1081–1087.
73. Patel, M., Fowler, D., Sizer, J., Walton, C., Faecal volatile biomarkers of Clostridium difficile infection. PLoS One, 14(4), 2019, e0215256.
74. Wan, Y., Wang, F., Yuan, J., et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: A 6-month randomised controlled-feeding trial. Gut, 2019, 1–31.
75. De Preter, V., Falony, G., Windey, K., Hamer, H.M., De Vuyst, L., Verbeke, K., The prebiotic, oligofructose-enriched inulin modulates the faecal metabolite profile: an in vitro analysis. Mol Nutr Food Res 54:12 (2010), 1791–1801.
76. Lecerf, J.M., Depeint, F., Clerc, E., et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 108:10 (2012), 1847–1858.
77. Cloetens, L., Broekaert, W.F., Delaedt, Y., et al. Tolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled cross-over study. Br J Nutr 103:5 (2010), 703–713.
78. Wahlstrom, A., Sayin, S.I., Marschall, H.U., Backhed, F., Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24:1 (2016), 41–50.
79. Yao, L., Seaton, S.C., Ndousse-Fetter, S., et al. A selective gut bacterial bile salt hydrolase alters host metabolism. Elife, 7, 2018.
80. Levy, M., Thaiss, C.A., Zeevi, D., et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163:6 (2015), 1428–1443.
81. Yazici, C., Wolf, P.G., Kim, H., et al. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut 66:11 (2017), 1983–1994.
82. Olson, C.A., Vuong, H.E., Yano, J.M., Liang, Q.Y., Nusbaum, D.J., Hsiao, E.Y., The gut microbiota mediates the anti-seizure effects of the Ketogenic diet. Cell, 174(2), 2018, 497.
83. Steed, A.L., Christophi, G.P., Kaiko, G.E., et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 357:6350 (2017), 498–502.
84. Koh, A., Molinaro, A., Stahlman, M., et al. Microbially produced imidazole propionate impairs insulin Signaling through mTORC1. Cell 175:4 (2018), 947–61 e17.
85. Madeo, F., Eisenberg, T., Pietrocola, F., Kroemer, G., Spermidine in health and disease. Science, 359(6374), 2018.
86. Weiss, T.S., Herfarth, H., Obermeier, F., et al. Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease. Inflamm Bowel Dis 10:5 (2004), 529–535.
87. Levy, M., Shapiro, H., Thaiss, C.A., Elinav, E., NLRP6: a multifaceted innate immune sensor. Trends Immunol 38:4 (2017), 248–260.
88. Thaiss, C.A., Levy, M., Korem, T., et al. Microbiota diurnal rhythmicity programs host Transcriptome oscillations. Cell 167:6 (2016), 1495–510 e12.
89. Thaiss, C.A., Zeevi, D., Levy, M., Segal, E., Elinav, E., A day in the life of the meta-organism: diurnal rhythms of the intestinal microbiome and its host. Gut Microbes 6:2 (2015), 137–142.
90. Thaiss, C.A., Zeevi, D., Levy, M., et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159:3 (2014), 514–529.
91. Thaiss, C.A., Levy, M., Elinav, E., Chronobiomics: the biological clock as a new principle in host-microbial interactions. PLoS Pathog, 11(10), 2015, e1005113.
92. Zwighaft, Z., Aviram, R., Shalev, M., et al. Circadian clock control by polyamine levels through a mechanism that declines with age. Cell Metab 22:5 (2015), 874–885.
93. Grizotte-Lake, M., Zhong, G., Duncan, K., et al. Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate interleukin-22 activity and prevent microbial dysbiosis. Immunity 49:6 (2018), 1103–15 e6.
94. Clemente, J.C., Manasson, J., Scher, J.U., The role of the gut microbiome in systemic inflammatory disease. BMJ, 360, 2018, j5145.
95. Wada, Y., Hisamatsu, T., Kamada, N., Okamoto, S., Hibi, T., Retinoic acid contributes to the induction of IL-12-hypoproducing dendritic cells. Inflamm Bowel Dis 15:10 (2009), 1548–1556.
96. Feng, F.E., Feng, R., Wang, M., et al. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol, 4(10), 2017 (e487-e96).
97. Nozaki, Y., Tamaki, C., Yamagata, T., et al. All-trans-retinoic acid suppresses interferon-gamma and tumor necrosis factor-alpha; a possible therapeutic agent for rheumatoid arthritis. Rheumatol Int 26:9 (2006), 810–817.
98. Smith, M.A., Adamson, P.C., Balis, F.M., et al. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10:11 (1992), 1666–1673.
99. Abdelhamid, L., Luo, X.M., Retinoic acid, leaky gut, and autoimmune diseases. Nutrients, 10(8), 2018.
100. Urdaneta, V., Casadesus, J., Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front Med (Lausanne), 4, 2017, 163.
101. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:2 (2006), 241–259.
102. Sayin, S.I., Wahlstrom, A., Felin, J., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:2 (2013), 225–235.
103. Selwyn, F.P., Csanaky, I.L., Zhang, Y., Klaassen, C.D., Importance of large intestine in regulating bile acids and glucagon-like Peptide-1 in germ-free mice. Drug Metab Dispos 43:10 (2015), 1544–1556.
104. Worthmann, A., John, C., Ruhlemann, M.C., et al. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med 23:7 (2017), 839–849.
105. Weingarden, A.R., Chen, C., Zhang, N., et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of Ileal Pouchitis associated with the infection. J Clin Gastroenterol 50:8 (2016), 624–630.
106. Jain, U., Lai, C.W., Xiong, S., et al. Temporal regulation of the bacterial metabolite Deoxycholate during colonic repair is critical for crypt regeneration. Cell Host Microbe 24:3 (2018), 353–63 e5.
107. Ma, C., Han, M., Heinrich, B., et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 360(6391), 2018.
108. Bayerdorffer, E., Mannes, G.A., Ochsenkuhn, T., Dirschedl, P., Wiebecke, B., Paumgartner, G., Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 36:2 (1995), 268–273.
109. Yoshimoto, S., Loo, T.M., Atarashi, K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:7456 (2013), 97–101.
110. Braune, A., Blaut, M., Bacterial species involved in the conversion of dietary flavonoids in the human gut. Gut Microbes 7:3 (2016), 216–234.
111. Cassidy, A., Minihane, A.M., The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am J Clin Nutr 105:1 (2017), 10–22.
112. Thaiss, C.A., Itav, S., Rothschild, D., et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature 540:7634 (2016), 544–551.
113. Rodriguez Vaquero, M.J., Manca de Nadra, M.C., Growth parameter and viability modifications of Escherichia coli by phenolic compounds and argentine wine extracts. Appl Biochem Biotechnol 151:2–3 (2008), 342–352.
114. Liu, C., Ma, J., Sun, J., et al. Flavonoid-rich extract of Paulownia fortunei flowers attenuates diet-induced Hyperlipidemia, hepatic Steatosis and insulin resistance in obesity mice by AMPK pathway. Nutrients, 9(9), 2017.
115. Thaiss, C.A., Shapiro, H., Elinav, E., Post-dieting weight gain: the role of persistent microbiome changes. Future Microbiol 12 (2017), 555–559.
116. Weng, Z., Patel, A.B., Panagiotidou, S., Theoharides, T.C., The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 135:4 (2015), 1044–52 e5.
117. Parker-Athill, E., Luo, D., Bailey, A., et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 217:1–2 (2009), 20–27.
118. Tsilioni, I., Taliou, A., Francis, K., Theoharides, T.C., Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6. Transl Psychiatry, 5, 2015, e647.
119. Wang, J., Ho, L., Zhao, W., et al. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28:25 (2008), 6388–6392.
120. Cohen, L.J., Kang, H.S., Chu, J., et al. Functional metagenomic discovery of bacterial effectors in the human microbiome and isolation of commendamide, a GPCR G2A/132 agonist. Proc Natl Acad Sci U S A 112:35 (2015), E4825–E4834.
121. Cohen, L.J., Esterhazy, D., Kim, S.H., et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549:7670 (2017), 48–53.
122. Thaiss, C.A., Microbiome dynamics in obesity. Science 362:6417 (2018), 903–904.
123. Uhr, G.T., Dohnalova, L., Thaiss, C.A., The dimension of time in host-microbiome interactions. mSystems, 4(1), 2019.
124. Hamer, H.M., Jonkers, D.M., Vanhoutvin, S.A., et al. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 29:6 (2010), 738–744.
125. Chen, G., Ran, X., Li, B., et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine 30 (2018), 317–325.
126. Grisham, M.B., Demichele, S.J., Garleb, K.A., Specian, R.D., Sulfasalazine or enteral diets containing fish oil or oligosaccharides attenuate chronic colitis in rats. Inflamm Bowel Dis 2:3 (1996), 178–188.
127. Mohammadi, S., Memarian, A., Sedighi, S., Behnampour, N., Yazdani, Y., Immunoregulatory effects of indole-3-carbinol on monocyte-derived macrophages in systemic lupus erythematosus: a crucial role for aryl hydrocarbon receptor. Autoimmunity 51:5 (2018), 199–209.